Lilly(Eli) & Company

NYSE: LLY
$887.16
+$1.61 (+0.2%)
Closing Price on October 4, 2024

LLY Stock Chart and Intraday Price

LLY Stock Data

Asset Type Stock
Exchange NYSE
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address LILLY CORPORATE CTR, DROP CODE 1094, INDIANAPOLIS, IN, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 743,142.26M USD
Shares Outstanding 950,164,000
Eli Lilly and Company is a global leader in pharmaceuticals, focusing on discovering, developing, and marketing a wide range of human medications. With a rich history dating back to 1876 and headquartered in Indianapolis, Indiana, it offers treatments for diabetes, including a comprehensive lineup of insulin products, and type 2 diabetes medications like Jardiance and Trulicity. The company also has a strong presence in oncology, rheumatoid arthritis, dermatology, mental health, and more, with notable products such as Alimta for cancer and Cymbalta for depression. Eli Lilly collaborates with various industry partners to enhance its product offerings.

LLY Articles

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 569.58% and currently trading at $885.25. The company has been around since 1876 and the...
Selecting stocks for the long haul can be a challenge. Here is what could be the best-performing stock in 2030 and why.
The pharmaceutical industry plays a crucial role in most of our everyday lives. From life-saving medication we need when we need it, to everyday pain remediation or allergy medications, big pharma...
Diversification is key in today’s investing world. Exchange-traded funds, or ETFs, offer a convenient and affordable way to achieve this. Think of them as baskets filled with a variety of stocks....
247 Wall St. Key Insights QQQ offers higher growth potential but comes with greater risk due to its reliance on tech stocks. VOO provides broad market exposure with lower risk and steady growth. ...
Pharma stocks have been on quite a nice run over the past year. A number of new catalysts have revitalized this sector, which I’m going to dive into with a few of these picks. Whether we’re...
Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what the company's prospects are for the next decade of growth.
Jim Cramer is probably the closest thing we have to stock market superstar influencer. The host of CNBC’s “Mad Money” show is entertaining and popular with a broad swath of investors who like...
Some of the best opportunities can still be found in obesity treatment stocks. Look at Viking Therapeutics (NASDAQ:VKTX), for example. Now trading at $57.80, we strongly believe it could easily rally...
As the high-growth trade fizzles out in September, even some top-tier secular growth plays will take an outsized hit to the chin. Undoubtedly, several investment themes, including generative AI and...
Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or send them into the pits of despair. The drug discovery...
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry. The...
Unless you have been living under the rock, you’d have heard of Nvidia’s (NASDAQ: NVDA) success story. All investors want a bite of this big business and those who missed out are now trying to...
Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to...
The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive. Indeed, the growth various weight loss drugs have seen is notable, with GLP-1 agonists...